期刊文献+

Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma 被引量:5

Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma
在线阅读 下载PDF
导出
摘要 Hepatocellular carcinoma(HCC) is the predominant form of primary liver cancer and represents the third leading cause of cancer-related death worldwide. Current available therapeutic approaches are poorly effective,especially for the advanced forms of the disease. In the last year,short double stranded RNA molecules termed small interfering RNAs(si RNAs) and micro interfering RNAs(mi RNA),emerged as interesting molecules with potential therapeutic value for HCC. The practical use of these molecules is however limited by the identification of optimal molecular targets and especially by the lack of effective and targeted HCC delivery systems. Here we focus our discussion on the most recent advances in the identification of si RNAs/mi RNAs molecular targets and on the development of suitable si RNA/mi RNAs delivery systems. Hepatocellular carcinoma(HCC) is the predominant form of primary liver cancer and represents the third leading cause of cancer-related death worldwide. Current available therapeutic approaches are poorly effective,especially for the advanced forms of the disease. In the last year,short double stranded RNA molecules termed small interfering RNAs(si RNAs) and micro interfering RNAs(mi RNA),emerged as interesting molecules with potential therapeutic value for HCC. The practical use of these molecules is however limited by the identification of optimal molecular targets and especially by the lack of effective and targeted HCC delivery systems. Here we focus our discussion on the most recent advances in the identification of si RNAs/mi RNAs molecular targets and on the development of suitable si RNA/mi RNAs delivery systems.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第30期8994-9001,共8页 世界胃肠病学杂志(英文版)
基金 Supported by"Fondazione Cassa di Risparmio of Trieste" the"Fondazione Benefica Kathleen Foreman Casali of Trieste" the"Beneficentia Stiftung"of Vaduz Liechtenstein the Italian Minister of Instruction,University Research(MIUR),PRIN 2010-11,No.20109PLMH2(in part)
关键词 SMALL interfering RNA MICRO interferingRNA Delivery HEPATOCELLULAR CARCINOMA Therapeuticpotential Small interfering RNA Micro interfering RNA Delivery Hepatocellular carcinoma Therapeutic potential
  • 相关文献

参考文献34

  • 1El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiologyand molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061].
  • 2Nordenstedt H, White DL, El-Serag HB. The changing patternof epidemiology in hepatocellular carcinoma. Dig Liver Dis2010; 42 Suppl 3: S206-S214 [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5].
  • 3El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683].
  • 4Colombo M. Multidisciplinary approach to hepatocellularcarcinoma. Preface. Dig Liver Dis 2010; 42 Suppl 3: S205 [PMID:20547304 DOI: 10.1016/S1590-8658(10)00205-7].
  • 5Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, PortaC, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, BorbathI, Hssinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,Bruix J. Sorafenib in advanced hepatocellular carcinoma. N EnglJ Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857].
  • 6Grassi G, Dawson P, Guarnieri G, Kandolf R, Grassi M.Therapeutic potential of hammerhead ribozymes in the treatmentof hyper-proliferative diseases. Curr Pharm Biotechnol 2004; 5:369-386 [PMID: 15320768 DOI: 10.2174/1389201043376760].
  • 7Grassi M, Cavallaro G, Scir-S, Scaggiante B, Dapas B, FarraR, Baiz D, Giansante C, Guarnieri G, Perin D, Grassi G. CurrentStrategies to Improve the Efficacy and the Delivery of NucleicAcid Based Drugs. Curr Signal Transduct Ther 2010; 5: 92-120[DOI: 10.2174/157436210791112163].
  • 8Scaggiante B, Dapas B, Farra R, Grassi M, Pozzato G, GiansanteC, Fiotti N, Grassi G. Improving siRNA bio-distribution andminimizing side effects. Curr Drug Metab 2011; 12: 11-23 [PMID:21222588 DOI: 10.2174/138920011794520017].
  • 9Dapas B, Farra R, Grassi M, Giansante C, Fiotti N, Uxa L,Rainaldi G, Mercatanti A, Colombatti A, Spessotto P, Lacovich V,Guarnieri G, Grassi G. Role of E2F1-cyclin E1-cyclin E2 circuit inhuman coronary smooth muscle cell proliferation and therapeuticpotential of its downregulation by siRNAs. Mol Med 2009; 15:297-306 [PMID: 19603101 DOI: 10.2119/molmed.2009.00030].
  • 10Farra R, Dapas B, Pozzato G, Scaggiante B, Agostini F, ZennaroC, Grassi M, Rosso N, Giansante C, Fiotti N, Grassi G. Effectsof E2F1-cyclin E1-E2 circuit down regulation in hepatocellularcarcinoma cells. Dig Liver Dis 2011; 43: 1006-1014 [PMID:21831731 DOI: 10.1016/j.dld.2011.07.007].

同被引文献17

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部